La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
SpringWorks Therapeutics Gestione
Gestione criteri di controllo 2/4
SpringWorks Therapeutics' Il CEO è Saqib Islam, nominato in Jul2018, e ha un mandato di 6.08 anni. la retribuzione annua totale è $ 18.35M, composta da 4% di stipendio e 96% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1% delle azioni della società, per un valore di $ 26.98M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.2 anni e 5 anni.
Informazioni chiave
Saqib Islam
Amministratore delegato
US$18.4m
Compenso totale
| Percentuale dello stipendio del CEO | 4.0% |
| Mandato del CEO | 6.1yrs |
| Proprietà del CEO | 1.0% |
| Durata media del management | 4.2yrs |
| Durata media del Consiglio di amministrazione | 5yrs |
Aggiornamenti recenti sulla gestione
Recent updates
SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy
Aug 07Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues
May 11
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
May 03SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear
Apr 25SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners
Apr 19We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Sep 20We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate
Jun 07We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Feb 22Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
Nov 09SpringWorks drops 21% as Allogene drops lead asset in combination study
Aug 10SpringWorks Therapeutics GAAP EPS of -$1.41 misses by $0.15
Aug 04Sizing Up SpringWorks Therapeutics
Jul 20Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?
Jun 06SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases
May 02Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth
Dec 30SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline
Dec 14SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Strong Position To Grow Its Business
Sep 15SpringWorks shows durable effect for neurofibroma therapy with long-term data
Jun 15SpringWorks teams up with Seagen to evaluate nirogacestat combo in multiple myeloma
Jun 07We're Interested To See How SpringWorks Therapeutics (NASDAQ:SWTX) Uses Its Cash Hoard To Grow
May 31SpringWorks Therapeutics EPS misses by $0.11
May 06Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$301m |
| Mar 31 2024 | n/a | n/a | -US$339m |
| Dec 31 2023 | US$18m | US$725k | -US$325m |
| Sep 30 2023 | n/a | n/a | -US$305m |
| Jun 30 2023 | n/a | n/a | -US$298m |
| Mar 31 2023 | n/a | n/a | -US$289m |
| Dec 31 2022 | US$15m | US$680k | -US$277m |
| Sep 30 2022 | n/a | n/a | -US$259m |
| Jun 30 2022 | n/a | n/a | -US$228m |
| Mar 31 2022 | n/a | n/a | -US$206m |
| Dec 31 2021 | US$18m | US$590k | -US$174m |
| Sep 30 2021 | n/a | n/a | -US$107m |
| Jun 30 2021 | n/a | n/a | -US$87m |
| Mar 31 2021 | n/a | n/a | -US$60m |
| Dec 31 2020 | US$8m | US$541k | -US$46m |
| Sep 30 2020 | n/a | n/a | -US$73m |
| Jun 30 2020 | n/a | n/a | -US$68m |
| Mar 31 2020 | n/a | n/a | -US$62m |
| Dec 31 2019 | US$3m | US$480k | -US$51m |
| Sep 30 2019 | n/a | n/a | -US$41m |
| Jun 30 2019 | n/a | n/a | -US$29m |
| Mar 31 2019 | n/a | n/a | -US$18m |
| Dec 31 2018 | US$2m | US$407k | -US$18m |
Compensazione vs Mercato: La retribuzione totale di Saqib ($USD 18.35M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 6.76M ).
Compensazione vs guadagni: La retribuzione di Saqib è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Saqib Islam (54 yo)
6.1yrs
Mandato
US$18,351,489
Compensazione
Mr. Saqib Islam, J.D. has been Chief Executive Officer and Director at SpringWorks Therapeutics, Inc. since August 2018. He serves as an Independent Director of Passage Bio, Inc. since March 2019. Mr. Isla...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 6.1yrs | US$18.35m | 1.0% $ 28.4m | |
| Chief Financial Officer | 5yrs | US$3.74m | 0.025% $ 715.3k | |
| Chief Operating Officer | 3.6yrs | US$6.64m | 0.24% $ 6.7m | |
| Chief Medical Officer | 3.1yrs | US$4.31m | 0.034% $ 958.8k | |
| Chief Accounting Officer | 4.4yrs | Nessun dato | 0.0083% $ 235.9k | |
| Chief Scientific Officer | less than a year | Nessun dato | Nessun dato | |
| Vice President of Communications & Investor Relations | 6.6yrs | Nessun dato | Nessun dato | |
| General Counsel & Secretary | 4.6yrs | US$2.83m | 0.018% $ 521.7k | |
| Chief People Officer | 4yrs | US$2.52m | 0.0065% $ 185.3k | |
| Chief Commercial Officer | 3.4yrs | US$4.94m | 0.014% $ 392.7k |
4.2yrs
Durata media
56yo
Età media
Gestione esperta: Il team dirigenziale di SWTX è considerato esperto (durata media dell'incarico 4.2 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 6.1yrs | US$18.35m | 1.0% $ 28.4m | |
| Independent Director | 5yrs | US$520.14k | 0.014% $ 404.7k | |
| Independent Chairman of the Board | 8.6yrs | US$545.14k | 0.41% $ 11.6m | |
| Director | less than a year | Nessun dato | Nessun dato | |
| Independent Director | 7yrs | US$508.45k | 0.014% $ 404.7k | |
| Independent Director | 2.1yrs | US$507.64k | 0.011% $ 306.3k | |
| Independent Director | 4.3yrs | US$520.14k | 0% $ 0 |
5.0yrs
Durata media
66yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di SWTX sono considerati esperti (durata media dell'incarico 5 anni).